Your current location:

KBI Appoints Jiming Ye (MD, PhD) as Chief Scientific Officer

2021-05-31
5205
Kunming, China, May 31, 2021

Kunming Biomed International (KBI) today announced the appointment of Jiming Ye (MD, PhD) as Chief Scientific Officer. Dr. Ye will join company executive team to lead the company’s internal and external drug discovery programs in collaboration with pharmaceutical, biotech as well as academic communities.


“ Dr. Ye is an accomplished research leader who brings more than 30 years of experience and expertise in a variety of disease areas including metabolic, NASH/liver fibrosis, cardiovascular as well as CNS disease models,” said Dr. Bob Zhang, CEO of KBI. “KBI has built strong leadership position in providing value-driven and translational non-human primate models to accelerate collaborators’ drug discovery and early development programs. Jiming is uniquely qualified to further strengthen KBI’s core competence and facilitate expansions of our internal technical and disease model platform development.”


“I am thrilled to join KBI at this this exciting time to further strengthen KBI’s leadership position in the field and look forward to contributing to KBI’s sustainable growth in the future.” said Jiming.


As a physician scientist, Dr. Jiming Ye is a proven leader who has established great track record of basic science accomplishment and application in translational medicine. He has published extensively in obesity, insulin resistance, diabetes and NASH field. He is the former diabetes group leader and Professor at RMIT University, Australia. Currently he serves as Honorary Professor at both RMIT University and Garven Institute of Medical Research, Australia and Visiting Professor at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. He has trained many research fellows and PhD students in the areas of metabolic disease and Pharmacology. Dr. Ye received his M.D. from Kunming Medical University in China and Ph.D. from University of Tasmania, Australia. Prior to RMIT University, he worked at Garven Institute of Medical Research as Senior Research Officer and Associate Professor. He also worked at Eli Lilly for the design and management of multi-center clinical trials (phase 2-4). 


Contact us if you need more information.

Copyright © 2024 Kunming Biomed International Ltd. All Rights Reserved     |Privacy Policy|Terms of Use|
4571 Boda Road, Chenggong, Kunming, Yunnan, 650500, China